Inspection delays hold back BeiGene’s Tevimbra progress once again

BeiGene will need to wait a bit longer for an FDA de­ci­sion on can­cer im­munother­a­py, Tevim­bra, cit­ing a de­lay in sched­ul­ing clin­i­cal site in­spec­tions. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.